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The Steep Ramp Anaerobic Test (SRAT) was developed as a clinical test of anaerobic leg muscle function for use in determining
anaerobic power and in prescribing high-intensity interval exercise in patients with chronic heart failure and Chronic Obstructive
Pulmonary Disease (COPD); however, neither the test-retest reliability nor the physiological qualities of this test have been
reported. We therefore, assessed test-retest reliability of the SRAT and the physiological characteristics associated with the test
in patients with COPD. 11 COPD patients (mean FEV1 43% predicted) performed a cardiopulmonary exercise test (CPET) on
Day 1, and an SRAT and a 30-second Wingate anaerobic test (WAT) on each of Days 2 and 3. The SRAT showed a high degree
of test-retest reliability (ICC = 0.99; CV = 3.8%, and bias 4.5W, error −15.3–24.4W). Power output on the SRAT was 157W
compared to 66W on the CPET and 231W on the WAT. Despite the diﬀerences in workload, patients exhibited similar metabolic
and ventilatory responses between the three tests. Measures of ventilatory constraint correlated more strongly with the CPET than
the WAT; however, physiological variables correlated more strongly with the WAT. The SRAT is a highly reliable test that better
reﬂects physiological performance on a WAT power test despite a similar level of ventilatory constraint compared to CPET.
1.Introduction
Individuals with Chronic Obstructive Pulmonary Disease
(COPD) are often prescribed aerobic exercise to enhance
function and reduce shortness of breath during activities of
daily living. General guidelines for this exercise prescription
suggest patients should exercise continuously at moderate
intensities [1–3]. There is evidence, however, to suggest that
exercise at higher intensities may be more beneﬁcial for this
population [4].
Traditionally,resultsfromcardiopulmonaryexercisetest-
ing (CPET) involving an incremental, graded exercise test
(GXT) of 8–12 minutes in duration, have been used to
prescribe exercise for individuals with COPD and are widely
considered to be the gold standard for measurement of
cardiopulmonary function and aerobic performance [5].
CPET, however, may underestimate the workload required
for optimal physiological beneﬁt from exercise training due
to ventilatory limitations causing early test cessation and a
blunted peak work rate [6, 7]. High-intensity interval exer-
ciseintensity may beprescribed forhealthyindividuals based
ontests ofanaerobic power and capacity, suchas a 30-second
WingateAnaerobicTest(WAT),whichisconsideredtobethe
gold standard measure of anaerobic capacity [8]; however,
these types of tests have not been widely used, nor would
be appropriate in typical clinical use for individuals with
COPD. However, the steep ramp anaerobic test (SRAT) has
been proposed as a clinical test that may more accurately
reﬂect leg muscle capabilities and better set interval training
intensities for individuals with chronic heart failure [7, 9, 10]
and COPD [11].
The SRAT was developed by Meyer et al. [7]f o ru s eb y
patients with heart failure to speciﬁcally challenge the mus-
clesmaximallybeforepatientsreachedacardiovascularlimit.
Unlike the WAT, in which subjects must pedal as fast as
possible against a ﬁxed resistance for 30 seconds, the SRAT2 Pulmonary Medicine
is an incremental GXT where the workload increases by
25 watts every 10 seconds until patient exhaustion [7, 10].
Much higher work rates are typically achieved with the SRAT
compared to the incremental CPET, and a percentage of
the peak work rate (PWR) from the SRAT can be used to
prescribe intervals for training in this population [10]. The
SRAT has also been used in COPD patients to prescribe
intensity for high intensity interval exercise [11]. The SRAT
may be better tolerated for use in populations that become
short of breath quickly during exercise because, and rather
than being a timed test like the WAT, it is patient-limited.
The test-retest reliability and the physiological responses of
the SRAT in this population remain unknown.
The purposes of this study were to determine (a) the
test-retest reliability of the SRAT in patients with COPD and
(b) the physiologic, ventilatory, and perceptual parameters
obtained on the SRAT compared with performance on a
traditional CPET or WAT in COPD patients.
2.MaterialsandMethods
2.1. Subjects. 11 patients (7 males and 4 females) with mod-
erate and severe COPD (11) were recruited through the
Saskatoon Pulmonary Rehabilitation Program and through
the Division of Respirology, Critical Care and Sleep Medi-
cine,UniversityofSaskatchewan.Subjectshadarespirologist
conﬁrmed diagnosis of COPD [12], did not require the
use of supplemental oxygen at rest or during exercise, and
had not been in hospital with an acute exacerbation within
the previous 6 weeks. Subjects were excluded if they had
cardiovascular or musculoskeletal disease that would prevent
them from completing heavy exercise.
This research was approved by the University of Saskat-
chewan Biomedical Ethics Committee. All subjects signed a
consent form and were advised that they could freely with-
draw from the study at any time.
2.2. Research Design. A randomized cross-over design was
used to assess subjects’ physiological, ventilatory, and per-
ceptual responses to the SRAT as compared to the CPET and
WAT. The subjects attended 3 sessions for testing, within a 3
week period, with at least 48 hours separating sessions. An
initial baseline assessment session included screening, assess-
ment of criteria for study admission, pulmonary function
tests, and an incremental CPET. The following 2 visits each
included a 30-second WAT and a SR test separated by one
hour. The second of these 2 visits was included in order to
establish the test-retest reliability of these measures. The
orderofthetestswasconstantbetweenvisitsbutrandomized
between subjects.
2.3. Pulmonary Function Testing and CPET. Resting pul-
monary function testing (FEV1,F V C ,R V ,T L C ,D LCO) was
performed according to established standards [13] (V6200C
Autobox and Vmax 229D gas analyzer, SensorMedics Corp.,
Yorba Linda, California, USA). CPET was performed using
established protocols [5] with a workrate increment of
5–15W/min on a mechanically braked cycle ergometer
(800 S, SensorMedics). The test was terminated when the
subject indicated voluntary exhaustion, or the revolutions
per minute fell below 60 and could not be increased with
encouragement. Peak work rate (CPETpeak), and all physi-
ologic, ventilatory, and perceptual measures were collected
and used in the analysis.
2.4. 30-Second Wingate Anaerobic Test (WAT). The WAT was
performed as per established protocol [8]. Subjects com-
pletedaself-paced5minutewarm-uponthecycleergometer
(Monark 894 E, Ergomedic). Subjects were given two prac-
tice trials where they were asked to pedal as fast as possible,
and one half the brake weight used for the actual WAT was
applied to the ﬂywheel for two seconds. This protocol was
repeated for a second practice trial. After a two minute
rest, the WAT was performed. Patients were instructed to
maintain the maximal velocity for 30 seconds against the full
break weight (females: 35g/kg [14] and males: 45g/kg [15]).
Continual standardized encouragement was given to the
patient throughout the entire test. The average power output
(WATavg) over the 30 seconds (which reﬂects anaerobic
capacity), and all physiologic, ventilatory, and perceptual
measures were collected and used in the analysis.
2.5. The Steep Ramp Anaerobic Test (SRAT). The SRAT was
performed as described by Meyer et al. [7]. Testing was
performed using the same equipment, with monitoring of
the same parameters as for the CPET and WAT. After a 2
minute unloaded warm-up, the intensity increased by 25
watts every 10 seconds. The test was terminated when the
subject indicated they could no longer continue or if the
revolutions per minute fell below 60rpm. Continual stan-
dardizedencouragementwasgiventothepatientthroughout
the entire test. The peak work rate (SRATpeak), and all phys-
iologic, ventilatory, and perceptual measures were collected
and used in the analysis.
2.6. Physiologic, Ventilatory, and Perceptual Measures. For all
three exercise tests, physiologic measurements (blood pres-
sure, heart rate (HR) and rhythm (3-lead ECG), oxygen sat-
uration (SpO2) (N-395, Nellcor)), and perceptual measures
(ratings of perceived exertion (RPE) for dyspnea and fatigue
(0–10 modiﬁed Borg scale)), were obtained at baseline, dur-
ing exercise, and end-exercise. Measurements including oxy-
gen consumption (VO2), carbon dioxide production (VCO2),
tidal volume (VT), minute ventilation (VE), and respiratory
rate(RR)wererecordedonabreath-by-breathbasisandwere
averaged in 10 second increments. Inspiratory capacity (IC)
maneuvers [16] were performed at baseline, during exercise,
and end-exercise. From these maneuvers, operational lung
volumes (end-expiratory lung volume (EELV) and end-
inspiratorylungvolume(EILV))werecalculatedateachtime
point. EELV was estimated as the diﬀerence between TLC
and IC, whereas EILV was estimated as the EELV plus VT.
The degree of ventilatory constraint at peak exercise was
evaluated by the inspiratory reserve volume (IRV; equals
TLC−EILV) and by the VT/IC ratio.Pulmonary Medicine 3
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Figure 1: (a) Bland-Altman plot of reliability of Wingate average power measurements (Wavg) between both sessions. Y-axis: The diﬀerence
between Wavg from one day to the next. X-axis: The average of Wavg between both days. (b) Bland-Altman plot of reliability of the steep
ramp peak power measurements (SRpeak) between both sessions. Y-axis: The diﬀerence between SRpeak from one day to the next. X-axis: The
average of SRpeak between both days.
Table 1: Subject characteristics.
Subject characteristics (n = 11)
Male:Female, (n)7 : 4
Age, years 71±3
Weight, kg 84.6 ±21.0
BMI, kg/m2 29.3 ±5.9
TLC, L (% predicted) 6.56±1.21 (108 ± 10)
RV, L (% predicted) 3.42±0.91 (151 ± 32)
FEV1, (L) (% predicted) 1.08 ±0.26 (43 ± 15)
FVC (L), (% predicted) 2.73 ±0.68 (83 ± 15)
FEV1/FVC, % 41 ± 10
Mean ± standard deviation. Abbreviations: TLC: total lung capacity, RV:
residual volume, FEV1: forced expiratory volume in 1 second, FVC: forced
vital capacity, pred = predicted.
2.7.StatisticalAnalysis. Test-retestreliabilityoftheSRATand
the WAT was analyzed using Intraclass correlations (ICC),
coeﬃcient of variation (CV), and Bland-Altman plots. The
analysis of the data comparing the CPETpeak,S R A T peak,
and the Wavg, as well as the ventilatory, physiological, and
perceptual measures for each of the three tests included
repeated measures analysis of variance (ANOVA). Tukey’s
posthocanalysiswasperformedwheresigniﬁcantdiﬀerences
were found. Pearson r correlations for the work rate,
ventilatory,physiological,andperceptualmeasuresofeachof
the three tests were also performed to determine signiﬁcant
relationships between measures. All statistical analyses were
performed using a signiﬁcance level of P<0.05.
3. Results
Subject characteristics are presented in Table 1. Both the
WAT and the SRAT demonstrated a high degree of test-retest
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Figure 2: Comparison of the cardiopulmonary exercise test peak
power (CPET), the steep ramp test (SRAT) peak power, and the
average power in the 30-second Wingate anaerobic test (WAT) in
watts. Results are presented as mean ±0.95 conﬁdence interval. ∗ =
P<0.05 versus SRAT.
reliability. ICC was 0.99 and 0.98, and the CV was 3.8%
and 8.6% for the SRAT and WAT, respectively. Bland-Altman
plots demonstrated a small degree of bias and error between
the 2 sessions for the SRAT (4.5W; −15.3–24.4W, resp.) and
the WAT (12.0W; −49.5–73.5W, resp.) (See Figures 1(a) and
1(b)).
Between-test physiological, ventilatory, and perceptual
data are presented in Table 2. In addition, Figure 2 shows
the mean work rates for the 3 tests. There were signiﬁcant
diﬀerences between CPETpeak,S R A T peak,a n dW avg (65.9 ±
35.6, 156.8 ± 67.9, and 231.2 ± 113.4W, resp.). There were
no diﬀerences between VO2, RR, SpO2,H R ,VE,I C ,I R V ,
EELV, and VT/IC measurements at peak exercise in each of4 Pulmonary Medicine
Table 2: End-exercise measures for cardiopulmonary exercise test (CPET), steep ramp test (SR), and Wingate anaerobic test (WAT)
presented with means and standard deviations.
End-exercise measures Tests
CPET SRAT WAT
PWR (CPET & SR) Wavg (WAT) 65.9 ±35.9 156.8 ±67.9∗† 231.2 ±113.4∗
VO2 (L/min) 1.11 ±0.46 1.07 ±0.41 0.99 ±0.45
VCO2 (L/min) 1.13 ±0.52 0.97 ±0.40 0.90 ±0.42∗
VE (L/min) 40.436 ±13.33 38.94 ±13.01 39.73 ±14.73
RER 1.00 ±0.13 0.90 ±0.07∗ 0.89 ±0.08∗
VT (L) 1.19 ±0.31 1.12 ±0.24 1.09 ±0.33
VT/IC (%) 76.5 ±13.07 0 .1 ±12.0∗ 70.4 ±13.8
IC/TLC (%) 24.1 ±4.72 5 .1 ±5.52 3 .5 ±4.0
EELV/TLC (%) 75.9 ±4.77 4 .9 ±5.57 6 .5 ±4.0
EILV/TLC (%) 94.0 ±4.79 2 .0 ±5.19 2 .9 ±4.2
IRV/TLC (%) 6.0 ±4.78 .0 ±5.17 .1 ±4.2
RR (breaths per minute) 34 ± 63 5 ± 83 7 ± 8
SpO2 (%) 91.5 ±3.09 2 .3 ±1.59 3 .3 ±3.9
HR (beats per minute) 111.9 ±20.9 109.8 ±19.7 116.9 ±22.0
HR (%pred) 75.3 ±14.77 3 .7 ±13.07 8 .5 ±14.5
Dyspnea 5.6 ±1.85 .5 ±2.1† 6.8 ±2.3
Leg Fatigue 5.7 ±1.75 .6 ±1.86 .2 ±1.9
Mean ± standard deviation. ∗: P<0.05. †indicates signiﬁcance from WAT. PWR: peak work rate, VO2:o x y g e nc o n s u m p t i o n ,VCO2: carbon dioxide
elimination,VE:minuteventilation,RER:respiratoryexchangeratio,VT:tidalvolume,IC:inspiratorycapacity,TLC:totallungcapacity,EELV:endexpiratory
lung volume, EILV: end inspiratory lung volume, IRV: inspiratory reserve volume, RR: respiratory rate, SpO2: oxygen saturation, HR: heart rate.
the 3 tests. VCO2 at peak exercise (VCO2peak) in the CPET was
higher than VCO2peak in the WAT. VCO2peak in the SRAT was not
signiﬁcantly diﬀerent from the other 2 tests. The respiratory
exchange ratio (RER) at end exercise in the CPET was higher
than both the SRAT and the WAT; however, the RER was
not signiﬁcantly diﬀerent between the SRAT and the WAT.
DyspneawassigniﬁcantlylowerintheSRATcomparedtothe
WAT; however, no diﬀerence in RPE in regards to leg fatigue
between the tests.
Table 3 shows the correlation coeﬃcients for the SRAT
test data with respect to the corresponding data on each of
the CPET and WAT tests. SRATpeak correlated strongly with
both the CPETpeak and the Wavg. Most ventilatory and phys-
iological parameters for the SRAT were found to correlate
signiﬁcantly with those on the CPET and WAT. Physiologic
exercise performance variables tended to correlate better
with the WAT, whereas ventilatory parameters tended to
correlate better with the CPET.
4. Discussion
The primary purpose of this study was to determine the test-
retest reliability of the SRAT. Our data demonstrate excellent
retest consistency. All subjects but one obtained the same
peak score on the SRAT between both test sessions. The
reliability of the WAT was similarly assessed to determine
the appropriateness of this test to be used as a criterion
measure of anaerobic capacity in patients with COPD.
Although reliability analysis of this test was not part of the
purposes of this study, we demonstrated that the WAT was
Table 3: Pearson’s r correlation coeﬃcients between end-exercise
measures during the SRAT and the cardiopulmonary exercise test
(CPET) and Wingate anaerobic test (WAT).
End-exercise measures
Tests
CPET WAT
PWR (CPET & SR) Wavg
(WAT) 0.887∗ 0.887∗
VO2 (L/min) 0.891∗ 0.939∗
VCO2 (L/min) 0.837∗ 0.926∗
VE (L/min) 0.800∗ 0.930∗
RER 0.549 0.615∗
VT (L) 0.907∗ 0.954∗
VT/IC (%) 0.838∗ 0.806∗
IC/TLC (%) 0.905∗ 0.873∗
EELV/TLC (%) 0.905∗ 0.873∗
EILV/TLC (%) 0.916∗ 0.880∗
IRV/TLC (%) 0.916∗ 0.880∗
RR (breaths per minute) 0.559 0.877∗
SpO2 (%) 0.499 −0.017
HR (bpm) 0.684∗ 0.955∗
∗indicates signiﬁcant correlation (P<0.05).
also a reliable measure. Reliability of the WAT has been
previously established in health individuals [17] and patients
with COPD using an abbreviated WAT [8]. Although the
reliabilityoftheSRAThasnotyetbeenreported,incremental
exercise tests of a smaller increment have demonstratedPulmonary Medicine 5
excellent reliability [18]; therefore, it is not surprising that
the SRAT would also do so. The SRAT has been used in
previousstudiesexaminingtheeﬀectsofexercisetraining[9–
11]; therefore, the results of the present study lend credibility
to the use of the SRAT as an outcome measure in these
previous, and future studies.
The secondary purpose of the present study was to
compare the exercise responses and performance variables
on the SRAT with those on the CPET and WAT. We demon-
strated that the SRAT results in higher peak power output
than the aerobic-based CPET, but lower than the anaerobic-
based WAT. Despite these work load disparities, there were
no diﬀerences in end-test oxygen consumption, heart rate,
ventilation, and levels of ventilatory constraint between
the tests. These ﬁndings complement those of Miyahara
et al. [19] who demonstrated that, during CPET, higher
ramp increments resulted in higher power outputs than
lower ramp increments, despite similar cardiorespiratory
responses; however, the ramp increment used in the SRAT
was much higher than that used previously. As has been
observed in patients with COPD during a CPET, limitations
on the ability of patients to increase ventilation during
exercise constrain performance, and consequently, oxygen
consumption and heart rate [20]. Our study supports this
assertion because we also found that mean values for peak
heart rate were not maximal at end-exercise. The similar
levels of metabolic demand and ventilatory limitation found
in the present study suggest subjects performing any of the
three tests are primarily limited by the inability to increase
ventilation, rather than by a physiologically maximal oxygen
consumption. Due to the short amount of time to complete
the SRAT (67 ± 27 seconds) [21] and the high power output
compared to the CPET, however, the SRAT elicits a greater
degree of leg muscle anaerobic power than the CPET. In
addition, the SRAT peak power was also strongly correlated
with WAT average power output. These factors combined
suggest that the SRAT may be a practical test of anaerobic
power, even in the setting of ventilatory limitation.
Ventilatory constraint at end-exercise is suggested by
an inability to further increase tidal volume due in part
to dynamic hyperinﬂation [20] and by nearing predicted
maximal ventilation. With dynamic hyperinﬂation, EELV
increases, IRV decreases, and therefore VT during exercise
occupies a large percentage of IC [20]. In the present study, it
wasassumedthatthepatientswouldbelimitedbyventilatory
factorsduring the CPET, in part due to reliance upon aerobic
metabolism and the requirement to ventilate in proportion
to aerobic demands. Therefore, it was also assumed that
patients would hyperinﬂate less, demonstrate less ventilatory
constraint (i.e., increased ventilatory reserve), and be limited
more by peripheral muscle performance during tests lasting
only 30–90 seconds (i.e., the SRAT). Despite the varying
exercise durations, however, the similar level of ventilatory
restrictionobserved at the endof the3 tests suggeststhis may
be a shared limiting factor in all of the tests. This common
limitation may help to explain the high degree of correlation
between the three tests.
The WATavg was signiﬁcantly larger than the SRATpeak,
and this may be partially related to the protocol design of the
tests. The anaerobic metabolism present at the beginning of
the WAT encourages high work rates without immediately
driving ventilation. The patients gave maximal eﬀort across
the 30 seconds without realizing the degree of dyspnea they
wouldincurduetotherequirementforacidbuﬀering,which
was often near the end, or after cessation, of the WAT.
Although not objectively measured in our study protocol,
posttesting dyspnea scores were often reported to increase
beyond the end-test values during immediate recovery from
the WAT. In contrast, the SRAT, although also at a very
high power output, builds incrementally to a patient-limited
maximum. Patients were better able to control the amount
of work performed prior to the development of disabling
dyspnea, and the posttest increase observed in the WAT did
not occur in the SRAT. For this reason, the SRAT seems to be
an appropriate compromise between the low peak work rate
oftheCPETandthehighworkrate,butdemandingrecovery,
oftheWAT.ThepoweroutputontheSRAT,albeitstatistically
lower than the WATavg, combined with the short duration of
the SRAT suggest that the SRAT reﬂects performance on an
anaerobic power test (WAT), while allowing the patients to
appropriately and safely manage their symptoms.
Since ventilation may have been a common limiting
factor between the 3 tests, stratifying the population into
categories of disease severity may have elicited diﬀerent
results in this study. Similarly, stratifying according to gender
may have shown some diﬀerences. These options may be
available in a study with a larger sample size.
ThisstudydemonstratesthattheSRATisahighlyreliable
measure of high-intensity muscle performance. In addition,
it supports the assertion that leg power is often markedly
underestimated in the traditional incremental design of the
CPET, and that exercise is frequently terminated before a
maximal muscular response has been achieved because of
ventilatory limitations [6, 7, 22, 23]. Performance on the
SRAT resulted in peak work rates 238% higher than that
of the CPET. This is comparable to the ﬁndings of both
Meyer et al. [10] and Puhan et al. [11], where SRATpeak was
approximately double the CPETpeak in chronic heart failure
and COPD patients, respectively. Although further research
is required, it is likely the SRAT would be more useful than
the CPET in assessing and establishing intensities forexercise
training that are suﬃciently high to elicit clinical gains in leg
muscle power and high-intensity performance.
5. Conclusions
The SRAT is a highly reliable, feasible, high-power test in
patients with COPD and may be useful in estimating leg
muscle power. CPET underestimates the capabilities of the
leg muscles to perform high levels of work, due to the
attainment of ventilatory limitations in COPD patients.
Despite similar degrees of ventilatory constraint, the SRAT
demonstrates markedly greater work rates and better reﬂects
anaerobic performance in this population. The SRAT may
thus be more suitable for prescribing high-intensity interval
exercise in order to increase the potential for training beneﬁt
in COPD patients.6 Pulmonary Medicine
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